Trials / Unknown
UnknownNCT02946216
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
Frequency and Abundance of ALK/ROS1/MET Mutations on Circulating Tumor DNA in Patients With Non-small Cell Lung Cancer Using Single Molecule Amplifcation and Re-sequencing Technology: a Perspective Observational Study
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- First People's Hospital of Hangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC
Conditions
- Non-small Cell Lung Cancer Stage III
- Non-Small-Cell Lung Cancer Metastatic
- Adenocarcinoma of Lung
- EGFR Wildtype
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | ctDNA analysis |
Timeline
- Start date
- 2016-11-01
- Primary completion
- 2017-11-01
- Completion
- 2018-11-01
- First posted
- 2016-10-27
- Last updated
- 2016-10-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02946216. Inclusion in this directory is not an endorsement.